OOIR: Observatory of International Research

Papers

(The TQCC of RMD Open is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Antirheumatic treatment, disease activity and risk ofStaphylococcus aureusbacteraemia in rheumatoid arthritis: a nationwide nested case–control study	154
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study	100
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism	87
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study	74
Concordance and agreement between different activity scores in polymyalgia rheumatica	74
Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use	71
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination	63
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cr	61
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2	60
CD73^low B-cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies	59
Associations of pain sensitisation with tender and painful joint counts in people with hand osteoarthritis: results from the Nor-Hand study	58
COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI – the French cohort study of SARS-CoV-2	57
Correction: Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider	56
Assessment and personalised advice for fatigue in systemic lupus erythematosus using an innovative digital tool: the Lupus Expert system for the Assessment of Fatigue (LEAF) study	54
Social media in advancing equity and collaboration in rheumatology: the CORDIALITY review	53
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritis	53
Correction: Multicentrer study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results	52
Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis	50
Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupu	49
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry	45
Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study	44
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study	43
Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan	42
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis	39
Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study	39

Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 tri	39
Declaration on the use of social media for rheumatology professionals	37
Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study	36
Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study	36
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance	36
Tolerability of low to moderate biomechanical stress during leisure sport activity in patients with psoriasis and psoriatic arthritis	35
Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study	34
Biomechanical determinants of rheumatoid arthritis severity and excess cardiovascular disease: common origins of two complex diseases	33
Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry	33
History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis	33
Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment	32
Trends in work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs): Data from the German National Database (2010–2022)	32
Personalised care packages for people with rheumatoid arthritis: a mixed-methods study	32
Machine learning using genotype and gene-expression data identifies alterations of genes involved in infection susceptibility, antigen presentation and cytokine signalling as key contributors to JIA r	32
A Thermographic Disease Activity Index for remote assessment of rheumatoid arthritis	30
Correction: Dissecting signalling pathways associated with intrarenal synthesis of complement components in lupus nephritis	30
Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis	30
Bilateral swelling of the salivary glands and sicca symptoms: an unusual differential diagnosis—Kimura’s disease, a rare allergic condition with a high IgE serum level—a case report and review of the	30
Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation	30
Long-term effectiveness of a lifestyle intervention for rheumatoid arthritis and osteoarthritis: 1-year follow-up of the ‘Plants for Joints’ randomised clinical trial	29
Comparison between primary Sjögren’s disease patients with high or low level of dryness	29
High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex	29
Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry	29
Different rheumatoid factor binding patterns distinguish between Sjögren’s disease with or without associated RA	29
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial	29
Pain sensitisation and joint inflammation in patients with active rheumatoid arthritis	29
Minimally invasive ultrasound-guided biopsy of the common extensor tendon enthesis: a cadaveric study to standardise the technique	29
Time sequence of autoimmune processes in the trajectory to rheumatoid arthritis development: what do we know?	28
Safe use of tocilizumab in pregnant women with Takayasu arteritis: three case studies	28
Engagement and attrition with eHealth tools for remote monitoring in chronic arthritis: a systematic review and meta-analysis	28
Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study	28
Autoantibodies directed against the angiotensin II type 1 receptor and the endothelin-1 type A receptor in patients with systemic sclerosis	28
JAK inhibition and the holy grail for pain control in early RA	28
Correction: Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study	27
The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD Consortium	27
Genetic dissection of HLA-DRB115:01* and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB115:01*	26
Patients with osteoporosis: children of a lesser god	26
Moderate and high disease activity levels increase the risk of subclinical atherosclerosis progression in early rheumatoid arthritis: a 5-year prospective study	25
Identification of the first signs or symptoms in different spondyloarthritis subtypes and their association with HLA-B27: data from REGISPONSER and RESPONDIA registries	25
Diagnostic accuracy in axial spondyloarthritis: a systematic evaluation of the role of clinical information in the interpretation of sacroiliac joint imaging	25
Allergic conditions and risk of rheumatoid arthritis: a Swedish case–control study	25
Safety of mycophenolate mofetil in systemic lupus erythematosus maintenance therapy: insights from the LUNA registry in a nationwide prospective cohort study	25
Correction: Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long- term extension study	25
Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy	25
Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observati	25
Spontaneous resolution of acute gout: mechanisms and therapeutic targets	24
Performances of machine learning algorithms in discriminating sacroiliitis features on MRI: a systematic review	24
Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment	24
Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated	24
Neoehrlichia mikurensis is uncommon in rheumatological patients receiving tumour necrosis factor inhibitors and in blood donors: a retrospective cohort study	24

Targeting the IL-17A pathway for therapy in early-stage tendinopathy	24
Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping	24
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inf	24
Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis	23
Gender equity in academic rheumatology: is there a gender gap at European rheumatology conferences?	23
Waiting for JAK inhibitor safety data	23
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND	23
Immune reactivity directed against the carbamylated fibrinogen α chain does not cross-react with citrullinated fibrinogen immunodominant peptides in patients with rheumatoid arthritis	23
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral	23
Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre	22
Multimorbidity burden predicts lower likelihood of remission and higher likelihood of disease flare in patients with rheumatoid arthritis	22
Systematic screening for multimorbidities in patients with inflammatory rheumatic diseases enhanced preventive medication use and reduced hospitalisations: an exposed-non-exposed study	22
Correction: Impact of filgotinib on pain control in the phase 3 FINCH studies	22
Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observatio	22
Rheumatoid arthritis and psoriatic arthritis: is the disease impact different? A large matching study at diagnosis and after 1 year of treatment	22
Clinically relevant differences in spinal mobility related to daytime performance in patients with axial spondyloarthritis	21
Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus	21
Acetylated bacterial proteins as potent antigens inducing an anti-modified protein antibody response	21
Chronic kidney disease in patients with psoriatic arthritis: a cohort study	21
Assessment of the minimal clinically important difference for the Health Assessment Questionnaire Disability Index in patients with arthralgia at risk for progression to rheumatoid arthritis	21
Active counselling and well-controlled disease result in a higher percentage of women with rheumatoid arthritis that breast feed: results from the PreCARA study	21
What are the hot topics in Japanese rheumatology? Go above and beyond	21
Differences in nailfold capillaroscopy findings between limited and diffuse cutaneous systemic sclerosis: a detailed analysis	21
Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort	21
Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients	21
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension	20
COVID-19-associated arthritis: an emerging new entity?	20
Premature coronary artery disease in patients with immune-mediated inflammatory disease: a population-based study	20
New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritis	20
Fetal and maternal morbidity in pregnant patients with Lupus: a 10-year US nationwide analysis	20
Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study	20
Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA	20
Pre-eclampsia is more common in women with active psoriatic arthritis in pregnancy: a population-based study	20
Association of peripheral CD8⁺ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus	20
Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study	19
External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic	19
Is there a mitochondrial DNA haplogroup connection between osteoarthritis and elite athletes? A narrative review	19
Prediction of progressive fibrosing interstitial lung disease in patients with systemic sclerosis: insight from the CRDC cohort study	19
Rituximab to treat prolidase deficiency due to a novel pathogenic copy number variation in PEPD	19
Impaired cardiorespiratory fitness in psoriatic arthritis: insights from cardiopulmonary exercise testing	19
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study	19
Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study	19
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study	19
Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients	19
Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe	19
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and mic	19
Do fatty lesions explain the effect of inflammation on new syndesmophytes in patients with radiographic axial spondyloarthritis? Results from the SIAS cohort and ASSERT trial	18
Third dose corrects waning immunity to SARS-CoV-2 mRNA vaccines in immunocompromised patients with immune-mediated inflammatory diseases	18
Myocardial infarction in ANCA-associated vasculitis: a population-based cohort study	18
The equivocal opposite effects of lower and higher body mass index at diagnosis on radiographic joint damage progression in early rheumatoid arthritis: an inception cohort study over 15 years	18
Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades	18
Diffusing capacity of lungs for carbon monoxide associated with subclinical myocardial impairment in systemic sclerosis: A cardiac MR study	18
Arrhythmia in patients with systemic sclerosis: incidence, risk factors and impact on mortality in a Swedish register-based study	18
Routine radiographs of hands and feet do not have diagnostic or prognostic value in patients with clinically suspect arthralgia: a large longitudinal study	17
Erdheim-Chester disease with Rosai-Dorfman-like lesions: treatment with methotrexate, anakinra and upadacitinib	17
CT informs detection and treatment options in rheumatoid arthritis complicated by pulmonary non-tuberculous mycobacterial disease from the FIRST registry	17
Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)	17
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study	17
Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network	17
Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical p	17
Work loss in patients with rheumatoid arthritis treated with abatacept, rituximab, tocilizumab or TNF inhibitors: a nationwide direct drug-to-drug comparison	17
Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study	17
Impact of the COVID-19 pandemic on work productivity in patients with spondyloarthritis: results from the Dutch SpA-Net registry	17
Gut-joint axis in knee synovitis: gut fungal dysbiosis and altered fungi–bacteria correlation network identified in a community-based study	17
Correction: Ultrasound assessment of degenerative muscle Sarcopenia: the university of barcelona ultrasound scoring system for Sarcopenia	17
Primary antibody deficiency-associated arthritis shares features with spondyloarthritis and enteropathic arthritis	17
Celebrating the global impact of rheumatology research: preface to the Viewpoint Article—‘What are the hot topics in Japanese rheumatology?—Go above and beyond’ by Yoshiya Tanaka, Japan	17
Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease	17
Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort	17
Free educational material on the EULAR school of rheumatology website	17
Comparative analysis of global practices in the management of colchicine-resistant familial Mediterranean fever: a CliPS network analysis	17
Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force	16
EULAR points to consider for including the perspective of young patients with inflammatory arthritis into patient-reported outcomes measures	16
Pilot study of tocilizumab monotherapy for active chronic periaortitis	16
Correction: Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance	16
Serum immunoreactivity to neurofilament-medium shows high sensitivity and specificity in patients with Behçet disease	16
Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren’s disease	16
Evaluating the participation of junior members and patient and healthcare professionals representatives in EULAR task forces: results from an international survey	16
Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory	16
Clusters in paediatric Behçet’s disease: a multicentre international study	16

Metabolic and molecular imaging in inflammatory arthritis	16
MUC5B promoter variant rs35705950, rare but significant susceptibility locus in rheumatoid arthritis-interstitial lung disease with usual interstitial pneumonia in Asian populations	16
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis	16
Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis	16
Integration of transcriptome and immunophenotyping data highlights differences in the pathogenetic kinetics of B cells across immune-mediated disease	16
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies	16
Anti-dsDNA IgE: a potential non-invasive test for prediction of lupus nephritis relapse	16
Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review	15
Elevated serum levels of interleukin-18 discriminate Still’s disease from other autoinflammatory conditions: results from the European ImmunAID cohort	15
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polya	15
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis	15
Evaluation of spondyloarthritis-specific health utility based on ASAS health index (U-ASAS-HI) among the disease subtypes: an ancillary analysis from the ASAS-PerSpA study	15
Mining the pathogenesis of rheumatoid arthritis, the leading role of the environment	15
Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study	15
Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort	15
Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study	15
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial	15
Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years	15
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis	15
Effectiveness of remote care interventions: a systematic review informing the 2022 EULAR Points to Consider for remote care in rheumatic and musculoskeletal diseases	14
Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases	14
Large language model-driven sentiment analysis for facilitating fibromyalgia diagnosis	14
Course of paediatric ANCA-associated glomerulonephritis: advocating for an age-inclusive approach	14
Severe methotrexate toxicity in elderly patients under diuretics	14
Incidence of collagen-induced arthritis is elevated by a high-fat diet without influencing body weight in mice	14
Burden of coronary artery calcification in ANCA-associated vasculitis	14
Increased prevalence of hearing loss, tinnitus and sudden deafness among patients with Sjögren’s syndrome	14
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study	14
Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease	14
Venous vessel-wall assessment with superb microvascular imaging in Behçet syndrome	14
Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses	14
Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial	14
Association between hyperuricaemia and hand osteoarthritis: data from the Xiangya Osteoarthritis Study	14
Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study	14
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks o	14
Methotrexate inhibits glucocorticoids-induced osteoclastogenesis via activating IFN-γR/STAT1 pathway in the treatment of rheumatoid arthritis	14
Hyperactivation and altered selection of B cells in patients with paediatric Sjogren’s syndrome	14
Correction: Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study	13
Association between body weight fluctuation and progression of radiographic knee osteoarthritis: a longitudinal cohort study	13
Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database	13
Depression, anxiety and cognitive function in persons with inflammatory rheumatic diseases: cross-sectional results from the German National Cohort (NAKO)	13
Association of a FAM13A variant with interstitial lung disease in Japanese rheumatoid arthritis	13
Grip strength reduction in clinically suspect arthralgia: natural trajectories and improvement after treatment	13
Correction: Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody	13
Distribution patterns of arterial affection and the influence of glucocorticoids on ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis	13
Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts	13
Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLO	13
Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce	13
Correction: miRNAs as potential biomarkers for subclinical atherosclerosis in sjögren’s disease	13
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider	13
Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease	13
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: a systematic review following COSMIN guidelines	13
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination	13
Endothelial dysfunction and increased carotid intima–media thickness in patients with spondyloarthritis without traditional cardiovascular risk factors	13
Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis	13
Identification of patient endotypes and adalimumab treatment responders in axial spondyloarthritis using blood-derived extracellular matrix biomarkers	13
Characteristics and outcome of critically ill patients with systemic rheumatic diseases referred to the intensive care unit	13
Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial	13
Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis	13
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project	12
Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening	12
Inflammation in the posterior elements, in particular the facet joint and facet joint ankylosis over 2-year follow-up in radiographic axial spondyloarthritis	12
Impact of rheumatoid arthritis and methotrexate on pregnancy outcomes: retrospective cohort study of the Italian Society for Rheumatology	12
Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials	12
Need and value of targeted immunosuppressive therapy in giant cell arteritis	12
Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition	12
Same, same or different? Commonalities and differences between spondyloarthritis and its subsets of axial and peripheral spondyloarthritis with psoriatic arthritis and its diverse phenotypes	12
Porphyromonas gingivalis associates with the presence of anti-citrullinated protein antibodies, but not with the onset of arthritis: studies in an at-risk population	12
Serum calprotectin and complement factor C3 are superior biomarkers of inflammation in early psoriatic arthritis as compared with C-reactive protein	12
Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis	12
Accrual of thromboembolic events and antiphospholipid syndrome in new-onset systemic lupus erythematosus: a population-based inception cohort study	12
Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry	12
Large language models for accurate disease detection in electronic health records: the examples of crystal arthropathies	12
Eosinopenia and routine inflammatory biomarkers are helpful for the diagnosis of infection in patients treated with IL-6 pathway antagonists	12
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis	12
Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis	12
Primary Sjögren’s syndrome independently promotes premature subclinical atherosclerosis	12
Hand osteoarthritis is associated with limitations in paid and unpaid work participation and related societal costs: the HOSTAS cohort	12
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III,	12
Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial	12
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials	12
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression	12
Safety, patient acceptance and diagnostic accuracy of ultrasound core needle biopsy of parotid or submandibular glands in primary Sjögren’s syndrome with suspected salivary gland lymphoma	12
Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study	11
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial	11
Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in p	11
Patients with VEXAS diagnosed in a Danish tertiary rheumatology setting have highly elevated inflammatory markers, macrocytic anaemia and negative autoimmune biomarkers	11
Joint distraction using a purpose-built device for knee osteoarthritis: a prospective 2-year follow-up	11
Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis	11
Utilisation of cardiovascular preventive services in a rheumatoid arthritis population-based cohort	11
MRI of shoulder girdle in polymyalgia rheumatica: inflammatory findings and their diagnostic value	11
Association between sinusitis and incident rheumatic diseases: a population-based study	11
Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible?	11
Effect of high-intensity interval training in physiotherapy primary care for patients with inflammatory arthritis: the ExeHeart randomised controlled trial	11
Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats	11